LOGIN  |  REGISTER
Chimerix

List of Medical Device Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 114.31
1.89 1.68
3.45M
1.73B
US$ 197.760B
US$ 527.22
2.79 0.53
902,962
356.18M
US$ 187.790B
US$ 366.49
1.89 0.52
1.06M
381.22M
US$ 139.710B
US$ 89.86
0.91 1.02
3.57M
1.47B
US$ 132.090B
US$ 81.40
0.37 0.46
5.77M
1.28B
US$ 104.190B
US$ 226.44
-1.24 -0.54
1.51M
290.01M
US$ 65.670B
US$ 74.81
0.00 0.00
3.81M
589.80M
US$ 44.120B
US$ 85.38
0.62 0.73
685,101
494.60M
US$ 42.230B
US$ 231.17
-6.10 -2.57
1.08M
146.80M
US$ 33.940B
US$ 329.57
-1.83 -0.55
361,133
72.42M
US$ 23.870B
US$ 106.82
-0.30 -0.28
1.39M
199.07M
US$ 21.260B
US$ 208.00
0.51 0.25
267,534
98.71M
US$ 20.530B
US$ 263.33
-3.24 -1.22
301,482
70.14M
US$ 18.470B
US$ 92.52
-0.92 -0.98
933,986
199.58M
US$ 18.470B
US$ 72.50
0.85 1.19
2.97M
226.94M
US$ 16.450B
US$ 29.18
-0.32 -1.08
4.76M
510.59M
US$ 14.900B
US$ 24.54
-0.12 -0.49
1.23M
435.99M
US$ 10.700B
US$ 83.10
0.47 0.57
771,247
113.74M
US$ 9.450B
US$ 240.55
-1.99 -0.82
162,451
38.38M
US$ 9.230B
US$ 167.51
-2.01 -1.19
325,374
53.54M
US$ 8.970B
US$ 57.39
0.39 0.68
1.38M
151.60M
US$ 8.700B
US$ 178.25
0.09 0.05
321,373
46.44M
US$ 8.280B
US$ 148.36
-2.52 -1.67
439,520
55.14M
US$ 8.180B
US$ 145.65
1.19 0.82
402,332
56.03M
US$ 8.160B
US$ 328.36
0.89 0.27
100,300
22.92M
US$ 7.530B
US$ 17.83
-0.17 -0.94
484,933
352.16M
US$ 6.280B
US$ 97.61
-0.61 -0.62
321,039
58.28M
US$ 5.690B
US$ 187.58
-0.19 -0.10
715,348
29.97M
US$ 5.620B
US$ 133.68
0.01 0.01
138,185
33.54M
US$ 4.480B
US$ 81.15
-0.02 -0.02
271,116
54.11M
US$ 4.390B
US$ 77.18
1.74 2.31
633,921
50.22M
US$ 3.880B
US$ 154.70
-2.12 -1.35
84,563
24.48M
US$ 3.790B
US$ 70.98
0.00 0.00
0
51.12M
US$ 3.630B
US$ 30.49
-0.31 -1.01
671,988
108.20M
US$ 3.300B
US$ 53.24
-2.21 -3.99
599,534
58.54M
US$ 3.120B
US$ 88.66
-1.73 -1.91
146,213
31.30M
US$ 2.780B
US$ 46.99
-0.60 -1.26
390,178
54.30M
US$ 2.550B
US$ 25.07
-0.11 -0.44
1.69M
101.66M
US$ 2.550B
US$ 36.61
0.70 1.95
826,921
65.68M
US$ 2.400B
US$ 50.03
-0.40 -0.79
450,934
45.58M
US$ 2.280B
US$ 69.18
0.55 0.80
348,683
30.89M
US$ 2.140B
US$ 62.65
0.95 1.54
924,462
33.56M
US$ 2.100B
US$ 91.38
-0.74 -0.80
130,997
22.48M
US$ 2.050B
US$ 22.01
0.21 0.96
301,562
77.16M
US$ 1.700B
US$ 30.51
-0.21 -0.68
183,789
48.75M
US$ 1.490B
US$ 34.59
0.93 2.76
688,679
40.30M
US$ 1.390B
US$ 10.17
-0.11 -1.07
1.13M
134.56M
US$ 1.370B
US$ 9.27
0.17 1.87
300,653
146.95M
US$ 1.360B
US$ 9.12
-0.23 -2.46
793,895
141.77M
US$ 1.290B
US$ 16.95
-0.13 -0.76
613,025
76.25M
US$ 1.290B
US$ 26.38
-1.01 -3.69
430,926
46.39M
US$ 1.220B
US$ 42.14
2.13 5.32
245,953
28.76M
US$ 1.210B
US$ 28.28
-0.20 -0.70
130,763
41.92M
US$ 1.190B
US$ 24.17
-0.65 -2.62
623,963
49.28M
US$ 1.190B
US$ 27.49
0.00 0.00
0
40.63M
US$ 1.120B
US$ 17.40
-0.58 -3.23
110,521
61.52M
US$ 1.070B
US$ 21.02
0.46 2.24
274,517
49.60M
US$ 1.040B
US$ 10.09
0.06 0.60
265,929
83.72M
US$ 844.730M
US$ 6.46
0.14 2.22
231,874
128.81M
US$ 832.110M
US$ 459.92
0.00 0.00
0
1.76M
US$ 809.460M
US$ 17.19
1.55 9.91
726,250
44.01M
US$ 756.530M
US$ 16.03
-0.05 -0.31
359,168
45.96M
US$ 736.740M
US$ 10.65
-0.02 -0.19
414,341
65.37M
US$ 696.190M
US$ 54.07
-0.58 -1.06
17,007
12.67M
US$ 685.070M
US$ 17.33
-0.10 -0.57
149,592
38.21M
US$ 662.180M
US$ 18.72
0.37 2.02
535,105
33.60M
US$ 628.990M
US$ 14.25
0.09 0.64
491,443
41.10M
US$ 585.670M
US$ 61.66
-0.12 -0.19
316,577
9.27M
US$ 571.590M
US$ 3.02
-0.07 -2.27
1.62M
186.64M
US$ 563.650M
US$ 13.16
-0.09 -0.68
212,235
41.94M
US$ 551.930M
US$ 22.62
0.24 1.07
98,016
24.22M
US$ 547.860M
US$ 4.10
-0.14 -3.30
265,173
105.48M
US$ 432.470M
US$ 6.94
-0.02 -0.29
162,113
62.30M
US$ 432.360M
US$ 7.07
0.31 4.59
2.64M
58.52M
US$ 413.740M
US$ 10.65
0.15 1.43
693,812
38.38M
US$ 408.750M
US$ 16.86
-0.14 -0.82
299,790
24.00M
US$ 404.640M
US$ 13.76
0.16 1.18
121,302
27.60M
US$ 379.780M
US$ 11.44
0.43 3.91
276,992
31.97M
US$ 365.740M
US$ 8.86
-0.03 -0.34
205,919
40.63M
US$ 359.980M
C$ 2.24
0.00 0.00
0
154.17M
C$ 345.340M
US$ 11.44
-0.09 -0.78
35,221
29.85M
US$ 341.480M
US$ 11.75
-0.02 -0.17
46,575
26.22M
US$ 308.080M
US$ 7.83
-0.15 -1.88
95,475
38.94M
US$ 304.900M
US$ 12.50
0.39 3.22
84,309
24.26M
US$ 303.250M
US$ 8.00
-0.01 -0.12
25,494
37.43M
US$ 299.440M
US$ 34.11
0.43 1.28
32,596
8.74M
US$ 298.120M
US$ 0.47
0.01 2.87
16.46M
595.33M
US$ 281.590M
US$ 3.62
-0.02 -0.55
2.19M
74.59M
US$ 270.020M
US$ 8.22
-0.03 -0.36
107,048
31.85M
US$ 261.810M
US$ 6.26
0.11 1.79
127,588
39.49M
US$ 247.210M
US$ 28.73
1.00 3.61
220,978
8.46M
US$ 243.060M
US$ 3.14
0.29 10.18
3.22M
67.59M
US$ 212.230M
US$ 7.00
-0.25 -3.45
498,218
30.03M
US$ 210.210M
US$ 61.13
0.11 0.18
29,721
3.39M
US$ 207.230M
US$ 6.03
-0.09 -1.47
232,649
33.70M
US$ 203.210M
US$ 8.43
-0.05 -0.59
90,775
23.82M
US$ 200.800M
US$ 2.35
0.00 0.00
804,135
84.73M
US$ 199.120M
US$ 22.75
-0.25 -1.09
10,108
8.53M
US$ 194.060M
US$ 1.87
0.02 1.08
546,480
100.56M
US$ 188.050M
US$ 3.95
-0.07 -1.74
84,967
45.84M
US$ 181.070M
US$ 3.51
-0.06 -1.68
146,088
50.40M
US$ 176.900M
US$ 8.15
-0.16 -1.93
87,298
21.26M
US$ 173.270M
US$ 9.15
-0.09 -0.97
33,181
18.81M
US$ 172.110M
US$ 45.90
-2.84 -5.83
8,723
3.26M
US$ 149.630M
US$ 3.77
-0.02 -0.53
343,202
37.47M
US$ 141.260M
US$ 0.90
0.04 4.65
222,157
156.55M
US$ 140.900M
US$ 4.42
-0.43 -8.78
83,402
30.25M
US$ 133.550M
US$ 4.13
0.08 1.98
21,938
30.49M
US$ 125.920M
US$ 2.36
-0.13 -5.22
131,897
49.56M
US$ 116.960M
US$ 2.93
0.08 2.81
233,200
39.39M
US$ 115.410M
US$ 17.52
2.25 14.73
213,012
6.55M
US$ 114.760M
US$ 6.87
-0.23 -3.24
410,910
16.39M
US$ 112.600M
US$ 2.41
-0.08 -3.21
981,659
43.09M
US$ 103.850M
US$ 8.75
1.05 13.64
159,546
11.61M
US$ 101.590M
US$ 0.35
0.00 0.00
0
272.84M
US$ 94.920M
US$ 14.97
-0.17 -1.12
9,864
6.27M
US$ 93.860M
US$ 2.10
-0.01 -0.47
132,224
43.62M
US$ 91.600M
US$ 2.50
-0.08 -3.10
59,772
34.31M
US$ 85.780M
US$ 2.22
0.03 1.37
86,022
37.10M
US$ 82.360M
US$ 2.95
-0.05 -1.67
9,077
26.08M
US$ 76.940M
US$ 4.64
0.00 0.00
17,069
16.04M
US$ 74.430M
US$ 1.18
0.00 0.00
122,515
59.23M
US$ 69.890M
US$ 12.92
0.92 7.67
56,872
5.25M
US$ 67.830M
US$ 0.87
-0.06 -5.95
151,418
77.89M
US$ 67.760M
US$ 1.90
-0.16 -7.77
327,198
34.82M
US$ 66.160M
US$ 3.50
0.00 0.00
0
17.86M
US$ 62.510M
US$ 1.66
0.09 5.73
52,580
37.64M
US$ 62.480M
US$ 1.18
-0.03 -2.48
337,618
52.54M
US$ 62.000M
US$ 1.12
-0.005 -0.45
471,893
55.50M
US$ 61.880M
C$ 0.25
-0.005 -2.00
75,195
247.78M
C$ 60.710M
US$ 0.41
0.05 13.89
194,996
139.01M
US$ 56.990M
US$ 0.13
0.04 46.12
4.01M
417.59M
US$ 53.450M
US$ 2.91
0.42 16.87
157,891
17.54M
US$ 51.040M
US$ 1.26
-0.13 -9.35
249,455
40.14M
US$ 50.580M
US$ 0.86
-0.02 -2.50
210,764
57.89M
US$ 49.960M
US$ 19.26
-0.29 -1.48
250,405
2.51M
US$ 48.340M
US$ 0.78
-0.006 -0.77
393,610
59.34M
US$ 45.990M
US$ 0.84
-0.08 -8.42
425,947
54.68M
US$ 45.820M
US$ 2.08
0.19 10.16
2.00M
19.51M
US$ 40.620M
US$ 5.60
2.48 79.74
19,732
6.63M
US$ 37.090M
C$ 0.40
-0.01 -2.47
56,500
93.38M
C$ 36.890M
C$ 0.30
-0.03 -9.09
19,500
119.77M
C$ 35.930M
C$ 0.31
0.00 0.00
30,092
113.10M
C$ 35.060M
US$ 0.91
0.01 1.33
109,738
37.72M
US$ 34.400M
US$ 2.62
-0.01 -0.38
1.32M
12.86M
US$ 33.690M
C$ 0.42
-0.005 -1.18
44,000
77.42M
C$ 32.520M
US$ 1.60
-0.05 -3.03
55,162
20.24M
US$ 32.380M
US$ 0.44
0.04 9.40
484,983
72.19M
US$ 31.840M
US$ 4.66
-0.07 -1.48
120,395
6.79M
US$ 31.640M
US$ 1.58
-0.06 -3.66
78,411
16.64M
US$ 26.290M
US$ 1.49
0.15 11.19
327,372
17.23M
US$ 25.670M
US$ 5.12
0.14 2.81
689,093
4.84M
US$ 24.780M
US$ 1.07
-0.02 -1.83
72,381
22.90M
US$ 24.500M
US$ 0.74
-0.02 -2.14
42,165
30.81M
US$ 22.860M
US$ 0.35
-0.001 -0.29
403,062
64.80M
US$ 22.490M
US$ 1.16
0.27 30.32
671,371
18.50M
US$ 21.460M
US$ 0.62
-0.02 -3.12
35,151
29.94M
US$ 18.560M
C$ 0.07
0.00 0.00
31,000
270.17M
C$ 17.560M
C$ 0.08
0.00 0.00
1,100
217.73M
C$ 17.420M
US$ 0.97
-0.0045 -0.46
102,336
16.93M
US$ 16.420M
C$ 0.10
0.00 0.00
5,000
159.67M
C$ 15.970M
US$ 1.49
-0.06 -3.57
6,837
10.54M
US$ 15.650M
C$ 0.03
0.00 0.00
421,112
451.63M
C$ 13.550M
US$ 2.17
0.00 0.00
0
6.24M
US$ 13.540M
US$ 0.61
0.02 4.29
60,661
22.00M
US$ 13.310M
US$ 1.49
-0.01 -0.67
59,794
8.81M
US$ 13.130M
US$ 2.88
-0.01 -0.35
4,495
4.17M
US$ 12.010M
US$ 0.50
0.03 6.38
53,070
20.86M
US$ 10.430M
US$ 1.99
-0.07 -3.40
134,364
4.46M
US$ 8.880M
US$ 0.12
0.00 0.00
0
73.90M
US$ 8.870M
US$ 0.32
0.01 3.62
901,022
26.09M
US$ 8.370M
US$ 3.95
0.05 1.28
26,536
2.04M
US$ 8.060M
US$ 0.55
-0.03 -4.48
30.15M
13.96M
US$ 7.730M
C$ 0.12
0.01 9.09
31,800
59.81M
C$ 7.180M
US$ 0.63
0.05 8.42
687,345
11.07M
US$ 6.990M
US$ 0.33
-0.04 -10.09
634,037
20.19M
US$ 6.600M
US$ 0.24
-0.17 -41.36
6,070
24.39M
US$ 5.930M
US$ 1.34
0.04 3.08
65,539
4.39M
US$ 5.880M
US$ 1.74
-0.10 -5.43
124,918
3.14M
US$ 5.460M
US$ 0.22
0.01 6.51
36.36M
23.46M
US$ 5.110M
US$ 0.28
0.0011 0.39
174,428
16.82M
US$ 4.710M
US$ 1.06
0.06 6.00
325,236
4.37M
US$ 4.630M
US$ 0.39
0.00 0.00
0
11.88M
US$ 4.630M
US$ 0.69
-0.0036 -0.52
80,689
6.67M
US$ 4.580M
US$ 0.91
0.003 0.33
58.18M
3.73M
US$ 3.410M
US$ 3.70
-0.13 -3.39
96,975
913,821
US$ 3.380M
US$ 1.85
-0.03 -1.60
24,724
1.80M
US$ 3.330M
US$ 0.30
0.03 11.11
12,500
10.59M
US$ 3.180M
US$ 1.72
-0.28 -14.00
191
1.82M
US$ 3.130M
US$ 0.35
0.02 5.15
79,641
8.00M
US$ 2.780M
US$ 0.03
-0.003 -10.00
10,873
96.71M
US$ 2.610M
US$ 0.99
-0.02 -2.18
469,661
2.46M
US$ 2.430M
US$ 0.32
-0.0027 -0.84
45,828
7.26M
US$ 2.320M
US$ 0.54
-0.04 -6.76
63,643
3.75M
US$ 2.030M
US$ 3.63
-0.21 -5.47
88,516
552,854
US$ 2.010M
US$ 0.61
0.13 25.98
1.11M
3.20M
US$ 1.950M
US$ 0.22
0.0054 2.52
1.20M
8.27M
US$ 1.820M
US$ 0.05
-0.04 -43.33
28,011
29.91M
US$ 1.530M
US$ 0.12
0.00 0.00
0
7.26M
US$ 871K
US$ 0.15
0.00 0.00
0
5.24M
US$ 792K
US$ 1.85
1.62 704.35
1,500
418,049
US$ 773K
US$ 0.39
-0.21 -35.00
834
1.78M
US$ 694K
US$ 0.001
0.00 0.00
0
15.85M
US$ 16K
US$ 0.0002
0.00 0.00
0
40.35M
US$ 8K
US$ 0.85
0.00 0.00
60,097
-
US$ -
US$ 0.00
0.00 0.00
0
855.04M
US$ -
US$ 6.06
0.00 0.00
16,151
-
US$ -
US$ 26.53
0.00 0.00
110,815
-
US$ -
C$ 0.61
0.00 0.00
1,500
-
C$ -
US$ 0.00
0.00 0.00
0
-
US$ -

Latest News From Medical Device Stocks


CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

MINNEAPOLIS, Dec. 23, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. The Company is scheduled to present at 2:15 PM Pacific Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s... Read more


AVITA Medical Announces FDA Approval of RECELL GO mini, Optimizing Treatment for Smaller Wounds

VALENCIA, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S. Food and Drug Administration (FDA) has approved its premarket approval (PMA) supplement for RECELL GO® mini. As a line extension of the RECELL GO system, the RECELL GO mini disposable cartridge is designed specifically... Read more


Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic

HOUSTON, TX, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS) of the brain, is pleased to announce the launch of Phase 1 of its proprietary virtual clinic. The virtual clinic will utilize artificial intelligence (AI) and Nexalin’s new Electronic Data Capture (EDC) platform and Patient Monitoring System (PMS). This AI ecosystem is designed to... Read more


Varex Imaging Announces Closing of Private Offering of $125 Million of Senior Secured Notes

SALT LAKE CITY / Dec 23, 2024 / Business Wire / Varex Imaging Corporation (Nasdaq: VREX) today announced it has closed its private offering (the “Offering”) of $125 million aggregate principal amount of 7.875% senior secured notes due 2027 (the “notes”) at an offering price of 101.5% of the principal amount thereof, plus accrued interest from and including October 15, 2024. “We are pleased to have successfully closed the offering of additional senior secured notes,”... Read more


Vivos Announces Launch of Groundbreaking RadioGel® Precision Radionuclide Therapy™ Human Clinical Trial

Richland, WA, Dec. 23, 2024 (GLOBE NEWSWIRE) -- – Vivos Inc. (OTCQB: RDGL) proudly announces the initiation of its first human clinical trial for RadioGel® Precision Radionuclide Therapy™ in India. This milestone trial, which has commenced with the successful treatment of five patients with cancerous lymph nodes, represents a transformative step in advancing innovative cancer therapies. This initial trial in India closely aligns with the protocol designed for... Read more


Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

ALISO VIEJO, Calif. / Dec 23, 2024 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Epioxa™ (Epi-on), its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus, a progressive,... Read more


Helius Medical Technologies Announces First Portable Neuromodulation Stimulator (PoNS®) System Sale to the Veterans Affairs (VA) Healthcare System

NEWTOWN, Pa., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the first PoNS System sale to the VA Healthcare System. The PoNS System sale through our distributor, Lovell Government Services (“Lovell”), was at the contracted price of $23,844, comprised of $16,499 for... Read more


SeaStar Medical Activates 14th Hospital for its Adult AKI Pivotal Trial

DENVER, Dec. 23, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that a 14th site is now activated and able to enroll subjects in the NEUTRALIZE-AKI pivotal trial. The NEUTRALIZE-AKI trial is evaluating the safety and efficacy of the Company’s proprietary therapeutic Selective Cytopheretic Device... Read more


Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

LITTLETON, Colo., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17), today announced that it... Read more


Merit Medical Systems Announces FDA Approval of the WRAPSODY Cell-Impermeable Endoprosthesis

Unique cell-impermeable1 design extends life-saving treatment for dialysis patients Merit to host a WRAPSODY informational call on January 28, 2025 SOUTH JORDAN, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that the WRAPSODY® Cell-Impermeable Endoprosthesis has received premarket approval from the US Food and Drug Administration (FDA). With... Read more


Aethlon Medical Provides Update on the Ability of Its Hemopurifier® to Capture H5N1 Bird Flu

SAN DIEGO, Dec. 20, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today provided a statement of its investigational medical device with respect to H5N1 avian influenza "Bird Flu." Aethlon has recently received a number of inquiries regarding the potential utility of its Hemopurifier device in the treatment of Bird Flu. These inquiries... Read more


Zimmer Biomet to Present at the 43rd Annual J.P. Morgan Healthcare Conference

WARSAW, Ind., Dec. 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 8:15 a.m. PT (11:15 a.m. ET). A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. The webcast will be archived for replay... Read more


Bruker Announces 1.2 GHz NMR Spectrometer at Swiss High-field NMR Facility

State-of-the-art instrument enhances research in structural biology and protein analysis ZÜRICH / Dec 20, 2024 / Business Wire / Bruker announces the acceptance of a 1.2 GHz Ascend™ Nuclear Magnetic Resonance (NMR) spectrometer at the Swiss High-field NMR Facility, operated jointly by the University of Basel, ETH Zürich, and the University of Zürich. This state-of-the-art instrument will significantly enhance the research capabilities of several user groups, enabling... Read more


AVITA Medical Announces FDA 510(k) Clearance for Cohealyx, Expanding its Addressable Market

New collagen-based dermal matrix designed for tissue generation, complementary to RECELL and PermeaDerm Cohealyx expected to triple AVITA Medical’s addressable market in burns VALENCIA, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S. Food and Drug Administration (FDA)... Read more


Modular Medical Announces Licensing and Partnership Agreement With Nudge BG

Modular Medical will collaborate with Nudge BG to bring to market an adaptive full closed loop Automated Insulin Delivery system that does not require mealtime announcements Effort will be led be Nudge BG founder and noted AID expert, Lane Desborough SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 19, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed... Read more


OraSure Technologies Acquires Sherlock Biosciences

BETHLEHEM, Pa., Dec. 19, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the acquisition of Sherlock Biosciences, Inc., a global health company bringing next-generation diagnostics to consumers and healthcare providers. This acquisition expands OraSure’s innovation pipeline with the addition of Sherlock’s molecular diagnostics platform,... Read more


Smith+Nephew introduces CORIOGRAPH™ Pre-Op Planning and Modeling Services for Total Hip Arthroplasty

Latest expansion to the CORI◊ Surgical System portfolio provides a personalized solution for patients and surgeons Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces its CORIOGRAPH Pre-Op Planning and Modeling Services is now cleared for total hip arthroplasty (THA) by the United States Food and Drug Administration. Exclusively for users of the CORI Surgical System, this innovative planning software allows for use of either X-rays... Read more


Envoy Medical Names Seven Investigational Sites for Participation in Its Pivotal Clinical Study

Initial patient enrollment anticipated during first quarter of 2025 White Bear Lake, Minnesota--(Newsfile Corp. - December 19, 2024) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company, today announces it has selected seven study sites for participation in its pivotal clinical trial to investigate its fully implanted Acclaim® cochlear implant (Acclaim CI). Initial patient enrollment is anticipated to begin during the first quarter of... Read more


Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia

NPM-115 clinical program utilizes a miniature, GLP-1 (exenatide) implant designed to provide comparable efficacy to semaglutide, with twice-yearly administration Study represents the first clinical application of NanoPortal™, the Company’s proprietary drug implant platform technology ALAMEDA, Calif. / Dec 19, 2024 / Business Wire / Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing novel, ultra... Read more


IRadimed to Present at the 43rd Annual J.P. Morgan Healthcare Conference

WINTER SPRINGS, Fla., Dec. 19, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (“MRI”) compatible medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system announced today that Roger Susi, Chief Executive Officer and Jack Glenn, Chief Financial Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference. The Company... Read more


Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters

Partnership launched with fully-contracted #CheckYourFoodTube Precancer Testing Event for Tuscaloosa firefighters NEW YORK, Dec. 19, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has entered into a strategic partnership with VITALExam LLC (VITALExam), a comprehensive medical care provider... Read more


Getinge and 908 Devices Partner to Enhance Bioreactor Capabilities for Continuous Monitoring of Key Cell Culture Parameters

BOSTON / Dec 19, 2024 / Business Wire / Today, 908 Devices Inc. (Nasdaq: MASS) and Getinge announce their collaboration to integrate Getinge’s bioreactors with 908 Devices’ MAVEN for automated control of glucose and lactate levels in cell cultures. The combined solution will help scientists measure critical process parameters in bioreactors, offering continuous, real-time analysis without the need for manual sampling. In the field of bioprocessing, the continuous monitoring... Read more


Conavi Medical Reports Fiscal 2024 Financial Results and Operational Highlights

Completed US$7.7 million financing and reverse takeover to take Company public Chinese partner achieved regulatory approval, setting stage for royalty stream and triggering US$5.9 million payment, enabling Company to fully repay debt to that partner U.S. FDA submission of Novasight 3.0 system on track for calendar 2025 TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“Conavi Medical” or the “Company”), a commercial stage medical... Read more


Baxter to Present at 43rd Annual J.P. Morgan Healthcare Conference

DEERFIELD, Ill. / Dec 18, 2024 / Business Wire / Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. José (Joe) E. Almeida, Baxter's chair, president and chief executive officer, is scheduled to present at 10:30 a.m. Pacific Time. The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through Saturday, July 12,... Read more


AVITA Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

VALENCIA, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025, at 9:00 a.m. Pacific Time. A live audio webcast of the presentation will be accessible under... Read more


NeuroPace to Present at the 43rd Annual J.P. Morgan Healthcare Conference

MOUNTAIN VIEW, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference at 4:30pm PT (7:30pm ET) on Wednesday, January 15, 2025, in San Francisco, CA. Management will also host investor meetings during the conference. The presentation will be accessible via... Read more


Iridex Announces Milestone Five-Year Study Confirms the Long-Term Effectiveness and Safety of MicroPulse Transscleral Cyclophotocoagulation for Glaucoma Management

MOUNTAIN VIEW, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced the publication of a landmark peer-reviewed study in Ophthalmology Therapy. This study highlights the sustained safety and efficacy of MicroPulse Transscleral Laser Therapy (TLT) (also referred to as Transscleral... Read more


GRAIL to Present at the 43rd Annual J.P. Morgan Healthcare Conference

MENLO PARK, Calif., Dec. 18, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15 at 9:00 a.m. PT.  Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived... Read more


RECOVER Clinical Study Shows Meaningful Benefits of LivaNova’s VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression

Results published in two articles in Brain Stimulation LONDON / Dec 18, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Brain Stimulation has published two pivotal articles chronicling the unipolar cohort data set for the RECOVER clinical study. The researchers evaluated the safety and efficacy of LivaNova’s VNS Therapy™ System and its effectiveness on quality of life and daily function... Read more


Intelligent Bio Solutions Announces 510(k) Submission to US FDA for Fingerprint Sweat-Based Drug Screening Technology

NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the submission of its 510(k) premarket notification to the US Food and Drug Administration (FDA) for clearance following FDA review of its Intelligent Fingerprinting Drug Screening System (the "System"), an innovative, rapid and pain-free method for... Read more


Hologic to Contribute to H5N1 Bird Flu Test Development via Agreement Issued by CDC

MARLBOROUGH, Mass. / Dec 18, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) today announced that it has entered into an agreement with the Centers for Disease Control and Prevention (CDC) to develop analyte specific reagents (ASRs) — the “active ingredients” of laboratory-developed tests used to identify specific diseases or conditions — that would aid in the detection of H5N1 bird flu. H5N1 bird flu, also known as avian influenza A (H5N1), continues to spread... Read more


VentriPoint Diagnostics and ASCEND Cardiovascular sign Term Sheet for integration of VMS+ into ASCEND's Gen3Echo(TM) platform

Toronto, Ontario – TheNewswire - December 18, 2024 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTCQB:VPTDF) is pleased to announce Ventripoint and ASCEND Cardiovascular, a leading provider of cardiovascular IT solutions, have signed a term sheet defining the general terms and conditions for a non-exclusive license to Ventripoint’s VMS+ proprietary technology.  The two parties expect to execute the license agreement within 30 days. ASCEND... Read more


Accuray: New Data Indicates the CyberKnife® System Can Provide a Safe and Effective Treatment Option to Control Brainstem Metastases, an Extremely Challenging Location to Treat

Study Builds on Extensive Published Literature Highlighting the Benefits of the CyberKnife System in the Treatment of a Wide Range of Neurological Indications MADISON, Wis., Dec. 18, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today an international retrospective multicenter analysis found that radiosurgery (SRS) and fractionated stereotactic radiotherapy (FSRT), delivered with the CyberKnife® System, can provide an effective and... Read more


Therma Bright Signs LOI For U.S. Distribution Network Expansion For Venowave With DME Authority

Initiative Includes Milestone-Based Inventory Purchase Commitments During Q1 and Q2, 2025 Toronto, Ontario--(Newsfile Corp. - December 18, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce the Company has signed a letter of intent (LOI) for a Venowave distribution program with DME Authority based... Read more


CooperCompanies to Present at the J.P. Morgan Healthcare Conference

SAN RAMON, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, today announced it will participate at the J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025. Al White, President and CEO, will represent the Company in a session scheduled to begin at 6:00 PM ET. A live and archived webcast of this event, where applicable, will be available by accessing the CooperCompanies’ website at http://investor.co... Read more


electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness

The Quell® platform will strengthen our position as a significant player in the bioelectronic health and wellness sector Company to discuss acquisition and host investor Q&A in a webcast today at 4:30 p.m. EST ROCKAWAY, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (“ECOR,” “electroCore,” or the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today it has entered into a definitive agreement... Read more


Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular Surgery

Preclinical data demonstrates advantages of the nano-PFA Cardiac Surgical System over radio frequency technology for ablation of cardiac tissue MIAMI / Dec 17, 2024 / Business Wire / Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced a new publication in the Journal of Thoracic and Cardiovascular Surgery. This preclinical study demonstrates the advantages... Read more


Abbott Announces First-in-World Leadless Pacing Procedures in the Left Bundle Branch Area of the Heart

Abbott's investigational AVEIR™ Conduction System Pacing (CSP) leadless pacemaker system is specifically designed to deliver pacing to the left bundle branch area, activating the heart's natural conduction system The device has received U.S. Food and Drug Administration Breakthrough Device Designation, which expedites the review of innovative technologies By creating a new pacing approach for the left bundle branch area of the heart, Abbott continues to pursue technologies... Read more


Quanterix Expands Capabilities with Strategic Acquisition of EMISSION

Builds technology capabilities through vertical integration of proprietary bead technology and drives OEM business BILLERICA, Mass. / Dec 17, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the acquisition of EMISSION iNC. (“EMISSION”). Quanterix expects the transaction will close in January 2025. “As we expand our technology... Read more


Becton Dickinson and Babson Diagnostics Launch Innovative Fingertip Blood Testing to Health Care Organizations

FRANKLIN LAKES, N.J. and AUSTIN, Texas, Dec. 17, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Babson Diagnostics, a science-first health care technology company, today announced an expansion of fingertip blood collection and testing technologies for use by U.S. health systems and other large provider networks in settings like urgent cares, doctor offices and other ambulatory care settings. This... Read more


VentriPoint Diagnostics Announces Closing of First Tranche of Amended Non-Brokered Convertible Debenture Private Placement

Toronto, Ontario, December 17, 2024 – TheNewswire - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”, TSXV:VPT) announces that it has closed the first tranche of its previously announced (see November 6, 2024 and December 9, 2024 press releases) amended non-brokered private placement of unsecured convertible debentures (“Debentures”). Ventripoint has issued an aggregate of $341,000 principal amount of Debentures with an issue price of $1,000... Read more


NeuroOne Medical Technologies Product Revenue Increases 77% to $3.5 Million in Fiscal 2024: Expects Product Revenue to Increase at Least 132% to at Least $8 Million in Fiscal 2025

Company’s Exclusive Distribution Agreement with Zimmer Biomet included $3.0 Million Upfront Payment: Expected to Drive Revenue and Expand Margins Significantly EDEN PRAIRIE, Minn., Dec. 17, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the... Read more


Quipt Home Medical Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Posts Strong Adjusted EBITDA Margin‎1 ‎for Fiscal Year 2024 and Returns to Positive Sequential Growth in Fiscal Q4 2024 CINCINNATI, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced its fourth quarter and fiscal year 2024 financial results and operational highlights. These results pertain to... Read more


Smith+Nephew expands AETOS™ Shoulder System with new stemless option for anatomic shoulder arthroplasty

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has received 510(k) clearance from the United States Food & Drug Administration for a stemless anatomic total shoulder for the AETOS Shoulder System (AETOS Stemless).  AETOS Stemless addresses the growing demand for anatomic total shoulder replacement with a small operating room footprint allowing for an efficient procedure.1 It is designed to maximize metaphyseal fixation... Read more


Envoy Medical Receives Additional Patent Protection for its Innovative Approach to Hearing Loss

WHITE BEAR LAKE, Minnesota , Dec. 16, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (NASDAQ: “COCH”), a hearing health company focused on providing hearing loss suffers with innovative solutions today announces four new patents. The US Patent & Trademark Office issued Envoy Medical Corporation US Pat. No. 12,151,102 on November 25, 2024. The title of the patent is Combination Hearing Aid and Cochlear Implant System. This patent relates to... Read more


enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

Successful Completion of All Planned Implants in GLP Study enVVe Delivery System Demonstrates Consistent Performance Company Maintains Timeline for IDE Application Submission by Mid-2025, Pending GLP Study Results IRVINE, CA / ACCESSWIRE / December 16, 2024 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the successful completion of the final wave... Read more


Data on IceCure Medical's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting

ICE3 trial results presented by ICE3 Co-Principal Investigator Dr. Kenneth Tomkovich FDA Advisory Panel voted in favor of IceCure's ProSense® cryoablation benefit-risk profile in early-stage low risk breast cancer in Nov. 2025 FDA's marketing authorization decision expected in Q1, 2025  CAESAREA, Israel, Dec. 16, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation... Read more


Treace Medical Concepts Announces First Surgical Cases Utilizing the SpeedPlate™ MicroQuad™ Implant

PONTE VEDRA, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the successful completion of the first cases utilizing SpeedPlate™ MicroQuad™ implants. The MicroQuad™ implant expands upon... Read more


Butterfly Network to Present at the 43rd Annual J.P. Morgan Healthcare Conference

NEW YORK & BURLINGTON, Mass. / Dec 16, 2024 / Business Wire / Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced that it will participate at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2025 at the Westin St. Francis in San Francisco, California. Joseph DeVivo, President, Chief Executive Officer & Chairman and... Read more


Varex Imaging Announces Private Offering of $125 Million of Senior Secured Notes

SALT LAKE CITY / Dec 16, 2024 / Business Wire / Varex Imaging Corporation (Nasdaq: VREX) today announced it has commenced a private offering (the “Offering”), subject to market and other conditions, of $125 million aggregate principal amount of its 7.875% senior secured notes due October 15, 2027 (the “notes”). The notes offered hereby will be issued as “Additional Notes” and will constitute a further issuance of our 7.875% senior secured notes due 2027, which... Read more

COPYRIGHT ©2023 HEALTH STOCKS HUB